PRTG_OUT_1 [2025-04-17 10:31:14 -0400] 4538 Bytes | 1245 tokens | Cum: 1245 tkns (15.56% of 8k)
==========================================================================

We need a winner today and it's already 10:31:13 AM on Thu Apr 17, 2025 -0400 ... So let's find out if Portage Biotech (PRTG) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 8.4900 up from 6.7500. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Portage Biotech (PRTG)
IPO: IPO date unknown
Market Cap: $13,591,409
Shares Outstanding: 1,120,000
Exchange: XNAS
Description: Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Here’s a list of headlines for Portage Biotech:

Mar-27-25 04:15PM - Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Mar-12-25 08:00AM - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Feb-12-25 04:15PM - Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Jan-30-25 04:30PM - Portage Biotech Announces Completion of $2.15 Million Private Financing
Jan-06-25 05:00AM - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
Dec-17-24 07:00AM - Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
Dec-12-24 04:15PM - Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
Nov-26-24 04:05PM - Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Prior AI Reports for PRTG:
1. 2025-03-27 – Score: 55 – Target: 7.2600 – Highs: 4.7583 / 13.2000 / 9.89
small-cap-company-shows-potential-despite-mixed-performance-indicators
2. 2025-03-24 – Score: 30 – Target: 4.9500 – Highs: 4.8000 / 4.4616 / 4.69
portage-biotech-high-insider-ownership-amid-negative-market-trends

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-12T12:00:00Z - Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
B2 - 2025-01-06T10:00:00Z - Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
B3 - 2024-07-22T09:24:37Z - Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket - Benzinga
B4 - 2024-04-17T17:36:19Z - Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B5 - 2024-04-12T12:01:00Z - Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
B6 - 2024-03-26T12:01:00Z - Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Portage Biotech (PRTG).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

PRTG_OUT_3 [2025-04-17 10:31:14 -0400] 956 Bytes | 262 tokens | Cum: 1509 tkns (18.86% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/12/3041325/0/en/Portage-Biotech-Resumes-Enrollment-in-Final-Cohort-of-Dose-Escalation-for-Port-6-in-ADPORT-601-Trial.htmlPortage Biotech announced the resumption of patient enrollment in the final cohort of the dose escalation stage for its selective A2A antagonist, PORT-6, within its ADPORT-601 Phase 1b clinical trial. The company is also preparing to evaluate the continuation of the study into its potent and selective A2B antagonist, PORT-7, and combination arms.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRTG_OUT_5 [2025-04-17 10:31:15 -0400] 924 Bytes | 291 tokens | Cum: 1802 tkns (22.53% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-11T18:18:42Z - Portage Biotech Shares Soar 94%...
A2 - 2025-04-11T17:06:11Z - 12 Health Care Stocks Moving In Friday's Intraday Session - CeriBell (NASDAQ:CBLL), CEL-SCI (AMEX:CV...
A3 - 2025-04-11T14:14:48Z - Nasdaq Gains Over 50 Points; JPMorgan Posts Upbeat Earnings - JPMorgan Chase (NYSE:JPM), Innovative ...
A4 - 2025-04-03T21:05:48Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Aldeyra Therapeutics (NASDAQ:ALDX)...
A5 - 2025-03-30T20:02:53Z - Small Cap Stocks To Add to Your Watchlist - March 29th...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PRTG_OUT_7 [2025-04-17 10:31:17 -0400] 1046 Bytes | 313 tokens | Cum: 2117 tkns (26.46% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Portage Biotech Shares Soar 94%**Date: 2025-04-11Source: {'uri': 'rttnews.com', 'dataType': 'news', 'title': 'RTTNews'}URL: https://www.rttnews.com/3528331/portage-biotech-shares-soar-94.aspxPortage Biotech Inc. (PRTG) surged 94.05 percent to $9.11 down $4.74 during Friday's trading, without any official news or filings to explain the move.

The biotech stock saw a significant increase in trading activity as it spiked from its previous close of $5.04 to an intraday high of $13.11.

PRTG opened at $5.14 and traded between $5.14 and $13.11 on volume of 22.7 million shares, sharply above its average of 598,000 on the Nasdaq. The stock has traded between $2.10 and $23.01 over the past 52 weeks.

For comments and feedback contact: [email protected]

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

PRTG_OUT_9 [2025-04-17 10:31:18 -0400] 238 Bytes | 59 tokens | Cum: 2178 tkns (27.22% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRTG_OUT_11 [2025-04-17 10:31:19 -0400] 251 Bytes | 78 tokens | Cum: 2259 tkns (28.24% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

PRTG_OUT_13 [2025-04-17 10:31:26 -0400] 4870 Bytes | 1192 tokens | Cum: 3454 tkns (43.18% of 8k)
==========================================================================

This is our set of metrics for Portage Biotech.
Please analyze the numbers.

+-------------------+-----------------------+-----------------------+----------------------+
| Volume: 318,139 | Perf Month: 88.72% | Option/Short: No / No | Sales Y/Y TTM: - |
+-------------------+-----------------------+-----------------------+----------------------+
| Avg Volume: 1.12M | Perf Quarter: 100.25% | Short Float: 192.76% | ROE: -194.84% |
+-------------------+-----------------------+-----------------------+----------------------+
| Rel Volume: 1.75 | Index: - | Short Ratio: 0.28 | ROI: -4812.45% |
+-------------------+-----------------------+-----------------------+----------------------+
| RSI (14): 58.83 | Market Cap: 8.89M | Short Interest: 0.31M | Sales Surprise: - |
+-------------------+-----------------------+-----------------------+----------------------+
| ATR (14): 1.59 | Shs Outstand: 1.12M | Beta: 0.99 | EPS Surprise: - |
+-------------------+-----------------------+-----------------------+----------------------+
| SMA20: 24.09% | Shs Float: 0.16M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-----------------------+----------------------+
| SMA50: 51.36% | Inst Own: 6.94% | Sales past 5Y: 0.00% | Earnings: Nov 26 AMC |
+-------------------+-----------------------+-----------------------+----------------------+
| SMA200: 64.21% | Insider Own: 75.46% | Employees: 7 | |
+-------------------+-----------------------+-----------------------+----------------------+
| Perf Week: 55.49% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+-------------------+-----------------------+-----------------------+----------------------+

The next section covers any insider trading by Portage Biotech officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.4
Average Volume: 2897453.74
30-Day High: 9.6
30-Day Low: 4.07
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Portage Biotech (PRTG).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Portage Biotech.

2) MARKET_SCORE[]
This conversation was initiated because PRTG is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for PRTG.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, PRTG could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect PRTG to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Portage Biotech.

11) ETHICAL_RATING[]
Rate Portage Biotech’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Portage Biotech.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

PRTG_IN_15 [2025-04-17 10:31:26 -0400] 126 Bytes | 29 tokens | Cum: 3715 tkns (46.44% of 8k)
==========================================================================

====================================
[2025-04-17 10:31:26] # Analysis Completed
Elapsed Time: 12.89 seconds